Clin­i­cians say ben­e­fits of CAR-T con­tin­ue to out­weigh risk of T-cell ma­lig­nan­cies

A day af­ter the FDA launched an in­ves­ti­ga­tion in­to rare cas­es of sec­ondary blood can­cer in pa­tients who re­ceived CAR-T ther­a­pies, clin­i­cians are call­ing it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.